Literature DB >> 3119350

Involvement of specific Lyt-2+ T cells in the immunological control of experimentally induced murine cutaneous leishmaniasis.

R G Titus1, G Milon, G Marchal, P Vassalli, J C Cerottini, J A Louis.   

Abstract

The involvement of Lyt-2+ T cells in the immunological control of cutaneous leishmaniasis was assessed by studying the course of the disease in mice in which the number of these cells was reduced by treatment with anti-Lyt-2 monoclonal antibody (mAb). Administration of anti-Lyt-2 mAb exacerbated Leishmania major-induced cutaneous lesions in both genetically resistant and susceptible mice. This effect correlated with a drastic reduction in the number of specific Lyt-2+ T cells generated during infection. These results, together with the observation that resistant mice possess higher numbers of specific Lyt-2+ T cells in lymph nodes draining their lesions than susceptible mice, 3 weeks after infection, indicate that Lyt-2+ T cells also play a role in the immunological control of Leishmania major-induced lesions.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3119350     DOI: 10.1002/eji.1830171007

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  29 in total

1.  Toward a novel experimental model of infection to study American cutaneous leishmaniasis caused by Leishmania braziliensis.

Authors:  Tatiana R de Moura; Fernanda O Novais; Fabiano Oliveira; Jorge Clarêncio; Almério Noronha; Aldina Barral; Claudia Brodskyn; Camila I de Oliveira
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  Reduced numbers of CD4+ suppressor cells with subsequent expansion of CD8+ protective T cells as an explanation for the paradoxical state of enhanced resistance to Leishmania in T-cell deficient BALB/c mice.

Authors:  J O Hill
Journal:  Immunology       Date:  1991-02       Impact factor: 7.397

Review 3.  Cutaneous leishmaniasis: a model for analysis of the immunoregulation by accessory cells.

Authors:  H Moll; U Ritter; S Flohé; K Erb; C Bauer; C Blank
Journal:  Med Microbiol Immunol       Date:  1996-02       Impact factor: 3.402

4.  Effect of CD4 monoclonal antibody in vivo on lesion development, delayed-type hypersensitivity and interleukin 3 production in experimental murine cutaneous leishmaniasis.

Authors:  F Y Liew; S Millott; R Lelchuk; S Cobbold; H Waldmann
Journal:  Clin Exp Immunol       Date:  1989-03       Impact factor: 4.330

5.  Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.

Authors:  Sylvie Bertholet; Alain Debrabant; Farhat Afrin; Elisabeth Caler; Susana Mendez; Khaled S Tabbara; Yasmine Belkaid; David L Sacks
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 6.  Escaping from rejection.

Authors:  Raymond J Lynch; Jeffrey L Platt
Journal:  Transplantation       Date:  2009-12-15       Impact factor: 4.939

7.  Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis.

Authors:  F P Heinzel; M D Sadick; S S Mutha; R M Locksley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

8.  Optimized subunit vaccine protects against experimental leishmaniasis.

Authors:  Sylvie Bertholet; Yasuyuki Goto; Lauren Carter; Ajay Bhatia; Randall F Howard; Darrick Carter; Rhea N Coler; Thomas S Vedvick; Steven G Reed
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

Review 9.  Leishmaniases of the New World: current concepts and implications for future research.

Authors:  G Grimaldi; R B Tesh
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

Review 10.  Dendritic cells in Leishmania major infections: mechanisms of parasite uptake, cell activation and evidence for physiological relevance.

Authors:  Kordula Kautz-Neu; Kirsten Schwonberg; Michael R Fischer; Anja I Schermann; Esther von Stebut
Journal:  Med Microbiol Immunol       Date:  2012-09-16       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.